



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 11

Complete if Known

Application Number	09/730,329
Filing Date	12/04/2000
First Named Inventor	John
Art Unit	1653
Examiner Name	Kam, C.
Attorney Docket Number	015270-006460US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CMK	153	6,852,482		02-08-2005	Gurney et al.	
	149	6,844,148		01-18-2005	Gurney et al.	
	148	6,835,565		12-28-2004	Gurney et al.	
	91 B2	6,828,117		12-07-2004	Gurney et al.	
	139	6,825,023		11-30-2004	Gurney et al.	
	113	6,797,487		09-28-2004	Gurney et al.	
	114	6,790,610		09-14-2004	Gurney et al.	
	115	6,753,163		06-22-2004	Gurney et al.	
	116	6,737,510		05-18-2004	Gurney et al.	
	117	6,727,074		04-27-2004	Gurney et al.	
	118	6,706,485		03-16-2004	Gurney et al.	
	119	6,699,671		03-02-2004	Gurney et al.	
	154	6,627,739		09-30-2003	Anderson	
	120	6,500,667		12-31-2002	Gurney et al.	
	121	6,440,698		08-27-2002	Gurney et al.	
	122	6,420,534		07-16-2002	Gurney et al.	
	1	6,361,975		03-26-2002	Christie et al.	
	2	6,358,725		03-19-2002	Christie et al.	
	138	6,329,163		12-11-2001	Anderson et al.	
	3	6,319,489		11-20-2001	Powell et al.	
	4	6,319,689		11-20-2001	Powell et al.	
	5	6,313,268		11-06-2001	Hook	
	6	6,245,884		06-12-2001	Hook	
	7	6,245,964		06-12-2001	McConlogue et al.	
CMK	8	6,221,645		04-24-2001	Chrysler et al.	

Examiner
Signature

[Signature]

Date
Considered

12/2/05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet 2 of 11

Application Number 09/730,329
Filing Date 12/04/2000
First Named Inventor John
Art Unit 1653
Examiner Name Kam, C.
Attorney Docket Number 015270-006460US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CHK	9	6,211,428		04-03-2001	Singh et al.	
	10	6,162,630		12-19-2000	Powell et al.	
	11	6,025,180		02-15-2000	Powell et al.	
	13	5,877,015		03-02-1999	Hardy et al.	
	141	5,863,756		01-26-1999	Barr et al.	
	14	5,849,560		12-15-1998	Abraham	
	15	5,837,672		11-17-1998	Schenk et al.	
	16	5,795,963		08-18-1998	Mullan	
	17	5,766,846		06-16-1998	Schlossmacher et al.	
	18	5,750,349		05-12-1998	Suzuki et al.	
	19	5,744,346		04-28-1998	Chrysler et al.	
	20	5,733,768		03-31-1998	Dixon et al.	
	21	5,593,846		01-14-1997	Schenk et al.	
	22	5,455,169		10-03-1995	Mullan	
	23	5,424,205		06-13-1995	Dovey et al.	
	140	2004/0234976		11-25-2004	Gurney et al.	
	123	2004/0166507		08-26-2004	Gurney et al.	
	124	2004/0048303		03-11-2004	Gurney et al.	
	125	2004/0043408		03-04-2004	Gurney et al.	
	128	2002/0081634		06-27-2002	Gurney et al.	
	130	2002/0037315		03-28-2002	Gurney et al.	
	131	2001/0021391		09-13-2001	Gurney et al.	
	142	10/817,979			Gurney et al.	
	143	10/477,076			Gurney et al.	
	144	09/668,314			Gurney et al.	
	94	09/548,370			Gurney et al.	
CHK	97	09/548,369			Gurney et al.	

Examiner
Signature

CHK

Date
Considered

12/2/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 11

Complete if Known

Application Number	09/730,329
Filing Date	12/04/2000
First Named Inventor	John
Art Unit	1653
Examiner Name	Kam, C.
Attorney Docket Number	015270-006460US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CTK	95	09/548,365			Gurney et al	
	27	09/404,133			Gurney et al.	
	28	09/277,229			Citron et al.	
	29	60/210,292			Hong et al.	
	30	60/178,368			Lin et al.	
	31	60/177,836			Lin et al.	
	152	60/169,232			Gurney et al.	
	32	60/168,060			Lin et al.	
	33	60/155,493			Gurney et al.	
	34	60/141,363			Lin et al.	
	35	60/139,172			Anderson et al.	
	36	60/119,571			Basi et al.	
	37	60/114,408			Basi et al.	
CTK	38	60/101,594			Gurney et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials ³	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
CTK	170	EP	1 445 263	A1	08-11-2004			
	171	EP	855 442	A2	07-29-1998			
	39	EP	855 444	A2	07-29-1998			
	40	EP	848 062	A2	06-17-1998			
	166	GB	2 364 059	B	01-14-2004			
	167	GB	2 389 114	B	02-04-2004			
	168	GB	2 389 113	B	02-04-2004			
	169	GB	2 389 182	B	02-04-2004			
CTK	134	WO	01/50829	A2	07-19-2001			

Examiner
Signature

[Signature]

Date
Considered

12/2/05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	4	of	11	Attorney Docket Number	015270-006460US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
CHK	135	WO	01/49098	A2	07-12-2001			
	136	WO	01/49097	A2	07-12-2001			
	48	WO	01/38487	A2	05-31-2001			
	49	WO	01/36600	A1	05-25-2001			
	50	WO	01/31054	A1	05-03-2001			
	51	WO	01/29563	A1	04-26-2001			
	137	WO	01/23533	A2	04-05-2001			
	52	WO	01/00665	A2	01-04-2001			
	53	WO	01/00663	A2	01-04-2001			
	47	WO	00/69262	A1	11-23-2000	English abstract only		
	46	WO	00/68266	A1	11-16-2000	English abstract only		
	45	WO	00/58479	A1	10-05-2000			
	44	WO	00/56871	A2	09-28-2000	English abstract only		
	43	WO	00/47618	A3	08-17-2000	English abstract only		
	42	WO	00/23576	A2	04-27-2000	English abstract only		
	41	WO	00/17369	A2	03-30-2000			
	54	WO	99/64587	A1	12-16-1999	English abstract only		
	55	WO	99/46281	A2	09-16-1999			
	57	WO	99/34004	A2	08-07-1999			
	59	WO	99/31236	A2	06-24-1999			
	145	WO	98/37226	A1	08-27-1998			
	60	WO	98/26059		06-18-1998			
	188	WO	98/22597	A2	05-28-1998			
	61	WO	98/21589		05-22-1998			
	62	WO	98/13488		04-02-1998			
	63	WO	98/11236		03-19-1998			
CHK	103	WO	97/47314		12-18-1997			
Examiner Signature					Date Considered	12/2/05		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	5	of	11	Attorney Docket Number	015270-006460US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
CMK	56	WO	96/40885	A2	12-19-1996			
I	58	WO	96/31122	A1	10-10-1996			
CMK	102	WO	96/20725	A2	07-11-1996			

Examiner Signature		Date Considered	12/2/05
-----------------------	---	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 60597020

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	6	of	11	Attorney Docket Number	015270-006460US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
CMK	104	BALDWIN et al., "Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design," <u>PNAS</u> , 90:6796-6800 (1993).		
	181	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000).		
	179	BROUN et al., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity," <u>Science</u> , 282:131-133 (1998).		
	105	BROWN et al., "Evaluation of Cathepsins D and G and EC 3.4.24.15 as Candidate β -Secretase Proteases Using Peptide and Amyloid Precursor Protein Substrates," <u>Journal of Neurochemistry</u> , 66:2436-2445 (1996).		
	106	CHEVALLIER et al., "Cathepsin D displays in vitro β -secretase-like specificity," <u>Brain Research</u> , 750:11-19 (1997).		
	64	CHYUNG et al., "Novel β -Secretase Cleavage of β -Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells," <u>Journal of Cell Biology</u> , 138:671-680 (1997).		
	178	DAS et al., "Estrogenic responses in estrogen receptor- α deficient mice reveal a distinct estrogen signaling pathway," <u>PNAS</u> , 94:12786-12791 (1997).		
	151	Declaration of Michael Bienkowski, Ph.D. in U.S. patent application 09/548,368		
	183	DENNIS et al., "Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa," <u>J. Biol. Chem.</u> , 269(35):22129-22136 (1994).		
	107	DIEDRICH et al., "Nucleotide sequence of a cDNA encoding mouse cathepsin D," <u>Nucleic Acids Research</u> , 18:7184 (1990).		
	65	Elan Corporation, plc and Pharmacia Corporation announce research collaboration, News 08/09/2000, www.elancorp.com.		
CMK	155	Examination Report for United Kingdom Application 00121314.9 dated November 1, 2002.		

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60597020

→

PTO/SB/08B (10-01)


Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/730,329
		Filing Date	12/04/2000
		First Named Inventor	John
		Art Unit	1653
		Examiner Name	Kam, C.
		Attorney Docket Number	015270-006460US
(use as many sheets as necessary)			
Sheet	7	of	11

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CHK	156	Examination Report for United Kingdom Application 00121314.9 dated July 21, 2003.	
	157	Examination Report for United Kingdom Application 00121314.9 dated October 30, 2003.	
	158	Examination Report for United Kingdom Application 0318112.0 dated November 19, 2003.	
	159	Search and Examination Report for United Kingdom Application 0318112.0 dated September 24, 2003.	
	160	Search and Examination Report for United Kingdom Application 0318107.0 dated September 25, 2003.	
	161	Search and Examination Report for United Kingdom Application 0318113.8 dated September 25, 2003.	
	162	Examination Report for United Kingdom Application 0318113.8 dated November 19, 2003.	
	163	Examination Report for European Application 00919298.0 dated October 30, 2003.	
	164	Search Report for European Application 04006991.6 dated June 11, 2004.	
	165	Examination Report for New Zealand Application 534876 dated August 27, 2004.	
	146	Examination Report for European Application 00919298.0 dated September 20, 2004.	
	184	International Preliminary Examination Report for PCT application PCT/US00/03819 dated 9/4/02.	
CHK	66	EVIN et al., "Alzheimer's disease amyloid precursor protein (βAPP): proteolytic processing, secretases and βA4 amyloid production," <u>Amyloid: Int. J. Exp. Clin. Invest.</u> 1:263-280 (1994).	

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60597020

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	8	of	11	Attorney Docket Number	015270-006460US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
CHK	67	HAASS et al., "Amyloid β -peptide is Produced by Cultured Cells During Normal Metabolism," <u>Nature</u> , 359:322-325 (1992).		
	68	HAASS et al., "The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β -Secretase Cleavage Within the Secretory Pathway," <u>Nature Medicine</u> , 12:1291-1296 (1995).		
	69	HAASS et al., " β -Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms," <u>Journal of Biochemistry</u> , 268:3021-3024 (1993).		
	147	HARDY, J., "Framing beta-amyloid," <u>Nature Genetics</u> , 1(4):233-234 (1992).		
	70	HIROSAWA et al., "Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain," <u>DNA Res.</u> , 6(5):329-336 (1999).		
	71	HUSSAIN et al., "Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase," <u>Molecular and Cellular Neuroscience</u> , 14:419-427 (1999).		
	176	JACKSON et al., "The p47 ^{phox} Mouse Knock-Out Model of Chronic Granulomatous Disease," <u>J. Exp. Med.</u> , 182:751-758 (1995).		
	72	KANG et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor," <u>Nature</u> , 325:733-736 (1987).		
	182	KICK et al., "Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D," <u>Chem. & Biol.</u> , 4:297-307 (1997).		
	73	KITAGUCHI et al., "Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity," <u>Nature</u> , 331:530-532 (1988).		
	74	KNOPS et al., "Cell-type and Amyloid Precursor Protein-type Specific Inhibition of A β Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases," <u>Journal of Biological Chemistry</u> , 270:2419-2422 (1995).		
CHK	75	KOO et al., "Evidence that Production and Release of Amyloid β -Protein Involves the Endocytic Pathway," <u>Journal of Biological Chemistry</u> , 269:17386-17389 (1994).		

Examiner Signature		Date Considered	12/2/05
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60597020

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	9	of	11	Attorney Docket Number	015270-006460US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CHK	173	KRISTIE, T. M., "The Mouse Homologue of the Human Transcription Factor C1 (Host Cell Factor)," <u>J. Biol. Chem.</u> , 272(42):26749-26755 (1997).	
	187	KUNTZ, I. D., "Structure-Based Strategies for Drug Design and Discovery," <u>Science</u> , 257:1078-1082 (1992).	
	174	Li et al., "Cloning and Characterization of Three New Murine Genes Encoding Short Homologues of RNase P RNA*," <u>J. Biol. Chem.</u> , 270(42):25281-25285 (1995).	
	108	MAJER et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," <u>Protein Science</u> , 6:1458-1466 (1997).	
	76	MULLAN et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β -Amyloid," <u>Nature Genetics</u> , 1: 345-347 (1992).	
	150	Office Action dated 5/6/02 in U.S. patent application 09/548,368	
	77	PCT Search report for PCT/US99/20881	
	78	PCT Search report for PCT/US00/03819	
	79	PONTE et al., "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," <u>Nature</u> , 331:525-527 (1988).	
	177	RAABE et al., "Knockout of the abetalipoproteinemia gene in mice: Reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes," <u>PNAS</u> , 95:8686-8691 (1998).	
	109	SAFTIG et al., "Amyloidogenic Processing of Human Amyloid Precursor Protein in Hippocampal Neurons Devoid of Cathepsin D," <u>Journal of Biological Chemistry</u> , 271:27241-27244 (1996).	
	110	SCHECHTER et al., "On the size of the active site in proteases. I. Papain," <u>Biochemical and Biophysical Research Communications</u> , 27:157-162 (1967).	
CHK	80	SEUBERT et al., "Secretion of β -amyloid Precursor Protein Cleaved at the Amino Terminus of the β -amyloid Peptide," <u>Nature</u> , 361:260-263 (1993).	
Examiner Signature			Date Considered
			12/2/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60597020

→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
(use as many sheets as necessary)				Attorney Docket Number	015270-006460US
Sheet	10	of	11		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
CMK	81	SINHA et al., "Purification and Cloning of Amyloid Precursor Protein β -Secretase from Human Brain," <u>Nature</u> , 402:537-540 (1999).		
	172	SUN et al., "Gene Structure, Chromosomal Localization, and Expression of the Murine Homologue of Human Proteinase Inhibitor 6 (PI-6) Suggests Divergence of PI-6 from the Ovalbumin Serpins", <u>J. Biol. Chem.</u> , 270(27): 16089-16096 (1995).		
	82	SZECSI, "The Aspartic Proteases," <u>Scand. J. Clin. Lab. Invest.</u> , 52 (suppl. 210): 5-22 (1992).		
	185	TANG et al., "Evolution in the Structure and Function of Aspartic Proteases," <u>J. Cellular Biochem.</u> , 33:53-63 (1987).		
	83	TANZI et al., "Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease," <u>Nature</u> , 331:528-530 (1988).		
	93	THOMPSON et al., "Expression and characterization of human β -Secretase from candidates metalloendopeptidase MP78 and cathepsin D in β APP-overexpressing cells," <u>Molecular Brain Research</u> , 48(2):206-214 (1997).		
	175	UMANS et al., "Targeted Inactivation of the Mouse α_2 -Macroglobulin Gene", <u>J. Biol. Chem.</u> , 270(34):19778-19785 (1995).		
	180	VAN DE LOO et al., "An oleate 12-hydroxylase from <i>Ricinus communis</i> L. is a fatty acyl desaturase homolog," <u>PNBS</u> , 92:6743-6747 (1995).		
	84	VASSER et al., " β -secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <u>Science</u> , 286(5440):735-741 (1999).		
	186	VISWANADHAN et al., "An Approach to Rapid Estimation of Relative Binding Affinities of Enzyme Inhibitors: Application to Peptidomimetic Inhibitors of the Human Immunodeficiency Virus Type 1 Protease," <u>J. Med. Chem.</u> , 39:705-712 (1996).		
CMK	85	YAN et al., "Membrane-anchored Aspartyl Protease with Alzheimer's Disease β -Secretase Activity," <u>Nature</u> , 402:533-537 (1999).		

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60597020

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/730,329
				Filing Date	12/04/2000
				First Named Inventor	John
				Art Unit	1653
				Examiner Name	Kam, C.
Sheet	11	of	11	Attorney Docket Number	015270-006460US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T ²
CMK	101	YOUNG et al., "HIV-1 Protease Inhibitors Based on Hydroxyethylene Dipeptide Isosteres: An Investigation into the Role of the P ₁ -Side Chain on Structure-Activity," <u>J. Med. Chem.</u> , 35:1702-1709 (1992).	
CMK	86	ZHAO et al., "β-Secretase Processing of the β-Amyloid Precursor Protein in Transgenic Mice Is Efficient in Neurons but Inefficient in Astrocytes," <u>Journal of Biological Chemistry</u> , 271:31407-31411 (1996).	

Examiner Signature		Date Considered	12/2/05
-----------------------	---	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60597020